The Second Affiliater Hospital of Nanchang University
Welcome,         Profile    Billing    Logout  
 7 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cheng, Xiaoshu
CSPPT2-TT, NCT04974151: China Stroke Primary Prevention Trial 2 for Participants with Hypertension and MTHFR 677 TT Genotype

Recruiting
4
24000
RoW
Amlodipine besylate, Amlodipine, Amlodipine besylate And Folic Acid, Amlodipine Folic Acid, Anye, 5-methyltetrahydrofolate (5-MTHF), 5-MTHF, Amlodipine placebo, Amlodipine (dummy), Amlodipine folic acid placebo, Amlodipine folic acid (dummy), 5-MTHF Placebos, 5-MTHF (dummy)
Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD
Hypertension, MTHFR 677 TT Genotype
06/29
06/29
CSPPT2-CC/CT, NCT04974138: China Stroke Primary Prevention Trial 2 for Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype

Recruiting
4
32000
RoW
Amlodipine besylate, Amlodipine, Amlodipine besylate and folic acid, Amlodipine folic acid, Anye, Amlodipine placebos, Amlodipine (dummy), Amlodipine-folic acid placebos, Amlodipine-folic acid (dummy)
Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The Affiliated Hospital Of Guizhou Medical University, Lianyungang Oriental Hospital, Tengzhou Central People's Hospital, First Affiliated Hospital Bengbu Medical College, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD
Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
06/29
06/29
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Recruiting
1/2
170
RoW
Lenvatinib + Envafolimab, Sunitinib
3D Medicines (Sichuan) Co., Ltd.
Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
12/24
12/24
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)

Active, not recruiting
N/A
539
RoW
BuMA Supreme, BuMA™
Sino Medical Sciences Technology Inc.
Coronary Artery Disease
03/18
12/25
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)

Active, not recruiting
N/A
1000
RoW
BuMA Supreme
Sino Medical Sciences Technology Inc.
Coronary Artery Disease
05/19
12/25
Cai, Limin
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Recruiting
1/2
170
RoW
Lenvatinib + Envafolimab, Sunitinib
3D Medicines (Sichuan) Co., Ltd.
Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
12/24
12/24

Download Options